This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
SM Stahl . Personalized Medicine, pharmacogenomics and the practice of psychiatry: on the threshold of predict therapeutics in psychopharmacology?
CNS Spectr. 2008; 13(2): 115–118.
DA Mrazek . Psychiatric Pharmacogenomics. New York: Oxford University Press; 2010.
CA Bousman . Commercial pharmacogenomics-based decision support tools in psychiatry. Lancet Psychiatry. 2016; 3(6): 585–590.
DL Braff , R Freedman . Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry. 2008; 165(8): 952–955.
AK Malhotra , GM Murphy , JL Kennedy . Pharmacogenetics of psychotropic drug response. Am J Psychiatry. 2004; 161(5): 780–796.
Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome wide analysis. Lancet. 2013; 381(9875): 1371–1379.
FE Lotrich . The emerging potential of pharmacogenetics in psychiatry. Am J Psychiatry. 2012; 169(7): 681–683.
CG Beevers , JE McGeary . Therapygenetics: moving towards personalized psychotherapy treatment. Trends Cogn Sci. 2012; 16(1): 11–12.
M Falcone , RM Smith , MG Chenoweth , et al. Neuroimaging in psychiatric pharmacogenetics research: the promise and the pitfalls. Neurospsychopharmacology. 2013; 38(12): 2327–2337.
MA Varela , TC Roberts , MJA Wood . Epigenetics and ncRNAs in Brain Function and Disease: mechanisms and prospects for therapy. Neurotherapeutics. 2013; 10(4): 621–631.
RH Perlis . Can single genes matter in a polygenic world?
Biol Psychiatry. 2010; 68(9): 783–784.
A Caspi , AR Hariri , A Holmes , R Uher , TE Moffitt . Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry. 2010; 167(5): 509–527.
AB Niculescu , D Levey , H Le-Niculescu , E Niculescu , SM Kurian , D Salomon . Psychiatric mood biomarkers: avoiding jumping to premature negative or positive conclusions. Mol Psychiatry. 2015; 20(3): 286–288.
SM Stahl . The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. CNS Spectr. 2013; 18(2): 65–68.
DA Morrissette , SM Stahl . Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. CNS Spectr. 2014; 19(5): 439–448.
SM Stahl , DA Morrissette , M Cummings , et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guideline. CNS Spectr. 2014; 19(5): 449–465.
G Ruaño , BL Szarek , D Villagra , et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med. 2013; 7(3): 429–439.
L Herbild , SE Andersen , T Werge , HB Rasmussen , G Jürgens . Does pharmacogenetic testing for CYP450 2D6 and 2C19 among patients with diagnoses within the schizophrenic spectrum reduce treatment costs?
Basic Clin Pharmacol Toxicol. 2013; 113(4): 266–272.
DK Hall-Flavin , JG Winner , JD Allen , et al. Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry. 2012; 2: e172.
DK Hall-Flavin , JG Winner , JD Allen , et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013; 23(10): 535–548.